Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Year: 2016
Type: article
Source: Blood
Authors: Irene M. Ghobrial, Ashraf Z Badros, James J. Vredenburgh, Jeffrey Matous, Aaron M. Caola, Alexandra Savell, Patrick Henrick, Claudia E. Paba-Prada, Robert L. Schlossman, Jacob P. Laubach, Jacalyn Rosenblatt, Andrew Yee, Jeffrey S. Wisch, Charles M. Farber, Rodrigo O. Maegawa, Saad Z Usmani, Joseph Cappuccio, Bradley Rivotto, Kimberly Noonan, Kaitlen Reyes, Nikhil C. Munshi, Kenneth C. Anderson, Paul Richardson
Institutions: Dana-Farber Cancer Institute, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Saint Francis Hospital & Medical Center, Colorado Blood Cancer Institute, Harvard University, Dana-Farber/Harvard Cancer Center, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Newton Wellesley Hospital, Morristown Medical Center, Carolinas Healthcare System, Levine Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2595743296